A Look At Financing, M&A And Alliance Activity October-December 2019
• By Amanda Micklus and Maureen Riordan
Device financing during 2019’s final quarter totaled $1.6bn, a substantial decrease from Q3’s $4.05bn. Merger and acquisition activity, almost doubled from the previous quarter reaching $6.1bn; Stryker’s 4.7bn takeover of Wright Medical was the only billion-dollar transaction. Financings by diagnostics/research players totaled $1.3bn (the lowest quarter of the year) and eight companies were acquired, five of which together were valued at $981m.
Device companies finished 2019 with $1.6bn, a substantial 60% decrease compared with the $4.05bn raised during Q3. Some financings types experienced increases, such as early-stage venture rounds and FOPOs, but debt offerings and IPOs were considerably down versus the last quarter. (See Exhibit 1.)
Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.
BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.
Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.
